Bicycle Therapeutics BCYC
NASDAQ BCYC
$4.30 +0.06 (+1.42%)
At close: Sep 4, 2026 · 4:00 PM EDT

Bicycle Therapeutics (BCYC) Net Income (2018 - 2026)

Bicycle Therapeutics' (BCYC) quarterly Net Income came in at -$50.3 million in Q2 2026, up 36.24% YoY from -$37.0 million in Q2 2025, and up 17.27% on a QoQ basis from -$60.9 million in Q1 2026.

Analysis

Bicycle Therapeutics (BCYC) Net Income (2018 - 2026) Analysis & Trends

Bicycle Therapeutics (BCYC) has 9 years of Net Income data on file, last reported at -$50.3 million in Q2 2026.

  • Quarterly Net Income rose 36.24% year-over-year to -$50.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$142.2 million (up 42.68% YoY) and the FY2025 annual result came in at -$170.8 million, up 2.32% from the prior year.
  • Net Income rose to -$50.3 million in Q2 2026, from -$60.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $28.1 million in Q4 2025 to a low of -$79.0 million in Q2 2025.
  • A 5-year average of -$42.1 million and a median of -$46.1 million in 2023 frame the typical range for Net Income.
  • The widest YoY moves for Net Income: up 148.66% in 2025, down 129.1% in 2025.
  • Tracing BCYC's Net Income over 5 years: stood at -$37.0 million in 2022, then sank by 34.01% to -$49.6 million in 2023, then retreated by 16.31% to -$57.6 million in 2024, then jumped by 148.66% to $28.1 million in 2025, then tumbled by 279.46% to -$50.3 million in 2026.
  • The last three Net Income figures came in at -$50.3 million (Q2 2026), -$60.9 million (Q1 2026), and $28.1 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Bicycle Therapeutics 299.81 Mn 299.81 Mn - -50.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -50.34 Mn
Mar 31, 2026 -60.85 Mn
Dec 31, 2025 28.05 Mn
Sep 30, 2025 -59.10 Mn
Jun 30, 2025 -78.95 Mn
Mar 31, 2025 -60.74 Mn
Dec 31, 2024 -57.65 Mn
Sep 30, 2024 -50.80 Mn
Jun 30, 2024 -39.81 Mn
Mar 31, 2024 -26.51 Mn
Dec 31, 2023 -49.57 Mn
Sep 30, 2023 -49.93 Mn
Jun 30, 2023 -42.60 Mn
Mar 31, 2023 -39.06 Mn
Dec 31, 2022 -36.99 Mn
Sep 30, 2022 -28.35 Mn
Jun 30, 2022 -26.83 Mn
Mar 31, 2022 -27.56 Mn
Dec 31, 2021 -19.06 Mn
Sep 30, 2021 -14.68 Mn